CD38

ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1

Score: 0.587 Price: $0.59 Medium Druggability Status: active Wiki: CD38

🧠 Neurodegeneration

HYPOTHESES

2

PAPERS

22

KG EDGES

313

DEBATES

1

3D Protein Structure

🧬 CD38 — PDB 1YH3 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Medium

Score: 0.61

Clinical Stage

Approved

Target Class

Enzyme

Safety

0.50

Druggability Analysis

Drug Development0.90

Structural Tractability0.95

Target Class0.85

Safety Profile0.50

Key Metrics

PDB Structures:

61

Known Drugs:

2

Approved:

2

In Clinical Trials:

0

Drug Pipeline (2 compounds)

2 Approved

Druggability Rationale: CD38 is highly druggable (0.90 score) due to its well-characterized catalytic site, extensive structural data (61 PDB structures at 1.45 Å resolution), and proven clinical validation with two approved monoclonal antibodies (daratumumab, isatuximab) demonstrating target engagement. The enzyme's defined NAD+ binding pocket and established mechanism make it amenable to both antibody and small molecule inhibitor approaches.

Mechanism: Monoclonal antibody targeting or small molecule inhibitor of NAD+ consuming activity

Drug Pipeline (2 compounds)

2 Approved

Known Drugs:

Daratumumab (approved) — Multiple myeloma

Isatuximab (approved) — Multiple myeloma

Structural Data:

PDB (61) ✓AlphaFold ✓Cryo-EM ✓

1YH3 1ZVM 2EF1 2EG9 2HCT+56 more

UniProt: H0Y950

🧬 3D Protein Structure

🧬 CD38 — PDB 1YH3 Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

CD38 has limited tissue selectivity concerns as a single gene target, but selectivity challenges may arise from its dual catalytic activities (ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase) requiring differentiated inhibition. Off-target risks for small molecule inhibitors include related ADP-ribosyl cyclases (CD157/BST-1), necessitating careful structural design to avoid cross-reactivity.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (8)

Relevant trials from ClinicalTrials.gov

Active

7

Completed

1

Total Enrollment

2,425

By Phase

PHASE1: 2 · PHASE2: 5 · PHASE3: 1

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in T Recruiting

PHASE3 NCT06918002 n=824

Multiple Myeloma, Newly Diagnosed

Interventions: Elranatamab, Lenalidomide (Revlimid®), Daratumumab SC (Darzalex)

Sponsor: Intergroupe Francophone du Myelome | Started: 2025-07-09

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Thera Recruiting

PHASE2 NCT06140966 n=54

Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma

Interventions: Daratumumab, Carfilzomib, Lenalidomide

Sponsor: Union Hospital, Tongji Medical College, Huazhong University | Started: 2023-10-20

A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cel Recruiting

PHASE2 NCT06860269 n=1200

Acute Lymphoblastic Leukemia

Interventions: Randomization + Blinatumomab + chemother, Randomization + Standard frontline T-ALL, Randomization + Isatuximab + Standard fr

Sponsor: Assistance Publique - Hôpitaux de Paris | Started: 2025-05-06

Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients Recruiting

PHASE2 NCT05665140 n=100

Newly Diagnosed Multiple Myeloma

Interventions: Isatuximab, Lenalidomide, Bortezomib

Sponsor: University Hopsital Schleswig Holstein Campus Lübeck | Started: 2023-02-03

A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM Active Not Recruiting

PHASE2 NCT04786028 n=72

Multiple Myeloma

Interventions: Isatuximab

Sponsor: Canadian Myeloma Research Group | Started: 2021-12-08

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Active Not Recruiting

PHASE2 NCT04835129 n=28

Multiple Myeloma

Interventions: Isatuximab (for run-in portion), Isatuximab (for expansion), Pomalidomide

Sponsor: Medical College of Wisconsin | Started: 2022-01-10

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma Active Not Recruiting

PHASE1 NCT04722146 n=140

Multiple Myeloma

Interventions: Teclistamab, Daratumumab, Pomalidomide

Sponsor: Janssen Research & Development, LLC | Started: 2021-03-12

A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With P Completed

PHASE1 NCT02918331 n=7

Multiple Myeloma

Interventions: Daratumumab (16 mg/kg), Lenalidomide, Dexamethasone

Sponsor: Janssen Pharmaceutical K.K. | Started: 2016-09

Linked Hypotheses (1)

CD38 Inhibition for NAD+ Restoration and Microglial Senescence Prevention0.575

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Knowledge Graph (20)

associated with (5)

CD38→neurodegenerationADORA2B→CD38P2RY12→CD38P2RX1→CD38P2RX4→CD38

co discussed (13)

MMP9→CD38SLC7A11→CD38AQP4→CD38CD38→C1QCD38→GPX4

▸ Show 8 more

CD38→PLA2G6CD38→MMP2CD38→C3CD38→PLA2G4ACGAS→CD38CD38→IL1BCD38→DNASE2CD38→STING1

interacts with (2)

CD38→NAMPTNAMPT→CD38

Debate History (1)

Should CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1) be prioritized a2026-04-21